Vulvovaginal Candidiasis Treatment Market Set to Reach US$1607 Million by 2033 with a Steady 4.5% CAGR Growth

The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in the healthcare sector the market is likely to propel to US$1607 Million by 2033.

VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals. The market is expected to grow due to an increase in R&D initiatives for precise diagnosis.

The high growth rate can be attributed to the rising disease burden of VVC and increasing testing rates. Positive changes, such as healthcare benefits by the government, increased awareness among consumers, and willingness to avail medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.

Attain a visually compelling report with accompanying graphs and charts. Request Sample @
 https://www.futuremarketinsights.com/reports/sample/rep-gb-15875

Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.

Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.

Key Takeaways from the Market Study

• As of 2023, the vulvovaginal candidiasis treatment market was valued at US$ 1035 Million
• From 2023 to 2033, the industry is poised to grow at a 4.5% CAGR
• By 2033, vulvovaginal candidiasis treatment market is slated to reach a valuation of US$ 1607 Million
• By route of administration, the oral segment accounted for the largest share of 43.2% and is expected to continue this trend over the forecast period.
• China is poised to yield a CAGR of 4.2% with respect to vulvovaginal candidiasis treatment in 2033

“Increasing prevalence of VVC cases and technological advancement in healthcare are expected to radically transform the vulvovaginal candidiasis treatment market in the coming years,” comments an analyst at FMI.

Be the leader of the pack with a flawlessly customized and influential report. @
https://www.futuremarketinsights.com/customization-available/rep-gb-15875

Competitive Landscape

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc.,Cadila Pharmaceuticals,Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.

These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,

• In October 2022 – Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
• In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential
• In July 2022 – Mycovia Pharmaceuticals, Inc. announced U.S. availability of VIVJOA (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Step Ahead of the Competition – Purchase Today@
https://www.futuremarketinsights.com/checkout/15875

Key Segments Covered in the Vulvovaginal Candidiasis Treatment Market Industry Survey

Vulvovaginal Candidiasis Treatment Market by Drug Class:

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

Vulvovaginal Candidiasis Treatment Market by Route of Administration:

• Oral Vulvovaginal Candidiasis Treatment
• Intravenous Vulvovaginal Candidiasis Treatment
• Topical Vulvovaginal Candidiasis Treatment

Vulvovaginal Candidiasis Treatment Market by Distribution Channel:

• Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
• Retail Pharmacy for Vulvovaginal Candidiasis Treatment
• Online Pharmacy for Vulvovaginal Candidiasis Treatment

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube